STYK1 and non-small cell lung carcinoma: This finding supports the role of STYK1 in modulating the sensitivity of NSCLC cells to EGFR TKI and suggests that expression levels of STYK1 could be a valuable biomarker to predict the long-term efficacy of EGFR TKI.